

## Round Table Case Discussions with:

---

Dr. Janessa Laskin  
Medical Oncologist  
BC Cancer Agency  
Vancouver, BC Canada

Dr. Alan Sandler  
Chief, Hematology/Oncology  
Oregon Health & Science Univ.  
Portland, OR USA

## Asian Never-Smoker with Adenocarcinoma (Part 2): Chemotherapy Options and Maintenance Therapy



with Howard (Jack) West, MD  
Medical Oncologist  
President & CEO  
GRACE

## Case: Background

---


- 53 year-old Asian never-smoking woman
- Presents with shortness of breath climbing stairs
- Chest x-ray: infiltrate in right lower lobe
- Chest CT: RLL infiltrate with solid component
  - additional lung nodules
- PET consistent with multifocal disease
- Biopsy: adenocarcinoma with BAC features
- EGFR mutation test – negative (EGFR “wild type”)

# ECOG 1594: Are All Platinum Doublets Essentially Equal?

- 1207 pts, stage IIIB/IV (15/85%), PS 0-2
- median age 63, M/F (64/36%)

<b>R A N D O M I Z E</b>	→	Cisplatin Paclitaxel	75 mg/m <sup>2</sup> d2 135 mg/m <sup>2</sup> /24h	Q3W
	→	Cisplatin Gemcitabine	100 mg/m <sup>2</sup> d1 1 g/m <sup>2</sup> d1,8,15	Q4W
	→	Cisplatin Docetaxel	75 mg/m <sup>2</sup> d1 75 mg/m <sup>2</sup> d1	Q3W
	→	Carboplatin Paclitaxel	AUC = 6 d1 225 mg/m <sup>2</sup> /3h d1	Q3W

Schiller, NEJM 346: 92-98, 2002




# \*IPASS: Gefitinib vs. Carbo/Paclitaxel as First Line Rx in Asian Never- or Light Ex-Smokers


## \*Iressa Pan-Asian Study



### EGFR mutation positive



### EGFR mutation negative



At risk :											
Gefitinib	132	108	71	31	11	3	0	91	21	4	2
C/P	129	103	37	7	2	1	0	85	58	14	1


Treatment by subgroup interaction test, p < 0.0001

Mok, NEJM 2009

# “Maintenance” Therapy with Avastin (Bevacizumab) on ECOG 4599 Trial

ECOG 4599

Sandler, *N Engl J Med.* 2006



## Eligibility

- Good performance status
- Non-squamous tumors
- No brain metastases,
- No therapeutic anti-coagulation
- No gross hemoptysis ( $\geq \frac{1}{2}$  tsp)

PD = progressive disease

# Maintenance Therapy: Is it Timing or Access to Subsequent Therapy?

